![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GlaxoSmithKline and LifeMine Join Forces for Fungi Drug Development
GlaxoSmithKline and LifeMine Join Forces for Fungi Drug Development
GlaxoSmithKline (GSK) has teamed up with Cambridge, Mass.-based LifeMine Therapeutics to develop small-molecule drugs derived from fungi.
The collaboration aims to identify up to three new drug candidates that could potentially address several disease areas.
Under the agreement, GSK will pay LifeMine $70 million upfront for access to the company’s drug discovery platform and LifeMine is also eligible for undisclosed milestone payments.
LifeMine CEO and co-founder Gregory Verdine said the company has a fungal genome repository of “an unprecedented scale,” adding that the collaboration is the first of its kind in which genomic drug discovery will be done using fungi.
Upcoming Events
-
21Oct